Drug eluting balloon
By designing a drug-eluting balloon with gap ventilation, the second cavity is fitted with the blood vessel wall, and extending the drug contact time, the problem of too short drug contact time in the prior art is solved, and the recurrence rate of blood vessel re-stenosis is reduced.
Patent Information
- Application Number
- CN202420326075.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Utility models(China)
- Current Assignee / Owner
- Filing Date
- 2024-02-21
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2034-02-21
AI Technical Summary
Existing drugs eluting the balloon blocks blood flow when it expands, resulting in the drug contact with the blood vessel wall for too short, affecting the treatment effect and increasing the recurrence rate of blood vessel restenosis.
Design a drug-eluting balloon, including a catheter and a through-tube, with a balloon at one end of the catheter, and the balloon is divided into a first cavity and a second cavity, the second cavity surrounds the outside of the first cavity and has an outer wall The two chambers are coated with drugs and the gaps are ventilated to ensure blood flow through and avoid blood flow blockage. The second chamber is attached to the blood vessel wall when it expands, extending the drug contact time.
Without blocking blood circulation, extending the contact time between the drug and the blood vessel walls improves the treatment effect and reduces the recurrence rate of blood vessel re-stenosis.
Smart Images

Figure CN221932836U_ABST
Abstract
Description
Technical Field
[0001] The utility model relates to the technical field of medical devices, in particular to a drug eluting balloon. Background Art
[0002] When the existing drug eluting balloon reaches the diseased part, the balloon expands and expands, which not only makes the drug on the balloon surface adhere to the blood vessel wall for drug administration, but also blocks the blood vessels in the diseased area, blocking the blood flow there, thereby affecting the blood pathways in the human body. Therefore, the balloon is generally inflated and expanded for 40 seconds, that is, the time that the drug on the balloon surface contacts the blood vessel wall is also 40 seconds. However, in such a short time, the amount of drug dissolved in the blood vessel wall is limited, which affects the treatment effect, thereby increasing the recurrence rate of blood vessel restenosis. Therefore, there is an urgent need for a drug eluting balloon that increases the contact time between the drug on the balloon surface and the blood vessel wall without blocking blood circulation, thereby reducing the recurrence rate of blood vessel restenosis. Utility Model Content
[0003] The technical problem to be solved by the utility model is to provide a drug eluting balloon, which increases the contact time between the drug on the balloon surface and the blood vessel wall without blocking blood circulation, thereby reducing the recurrence rate of blood vessel restenosis.
[0004] In order to solve the above technical problems, the technical solution adopted by the utility model is: a drug eluting balloon, comprising:
[0005] A catheter, wherein a balloon is provided at one end of the catheter, the balloon comprising a first cavity and a second cavity, the second cavity being an annular structure surrounding the outside of the first cavity, the outer wall of the second cavity being provided with a drug coating, the second cavity being communicated with the first cavity, a gap being provided between the first cavity and the second cavity, an inflation port being provided at one end of the catheter away from the balloon, and when the balloon is in a filled state, the first cavity is away from the blood vessel wall, and the second cavity is in contact with the blood vessel wall;
[0006] A through pipe is fixedly connected to the inside of the catheter, the through pipe is coaxial with the catheter, the outer wall of the through pipe and the inner wall of the catheter form a cavity, the inflation port is connected to the cavity, and an air inlet is provided at the first cavity, which is connected to the cavity.
[0007] Furthermore, the first cavity and the second cavity are connected through a cavity channel.
[0008] Furthermore, there are four cavities.
[0009] Furthermore, the catheter is provided with a plurality of developing marks at the balloon portion, and the plurality of developing marks are located on the outer wall of the catheter.
[0010] Furthermore, the distance between the outer wall of the through-tube and the inner wall of the conduit is 5 mm.
[0011] The beneficial effect of the utility model is that when the balloon reaches the expected lesion site, the first cavity expands first and then drives the second cavity to expand, so that the outer wall of the second cavity fits the blood vessel wall, and blood flows between the first cavity and the second cavity, thereby avoiding the situation in which the balloon expansion blocks the blood flow in the prior art. Therefore, for the drug balloon catheter of the utility model, the balloon in the expanded state can last for a long time in the lesion area, so that the drug on its surface is fully in contact with the lesion site, ensuring the treatment effect of the interventional surgery and reducing the recurrence rate of stenosis at the lesion site. BRIEF DESCRIPTION OF THE DRAWINGS
[0012] Figure 1 This is a schematic diagram of the structure of a drug eluting balloon according to a specific embodiment of the utility model;
[0013] Figure 2 for Figure 1 A-direction cross-sectional view.
[0014] Description of symbols
[0015] 1. Catheter; 11. Inflation port; 12. Development mark; 2. Balloon; 21. First cavity; 211. Air inlet; 22. Lumen; 23. Second cavity; 231. Drug coating; 3. Through tube; 4. Cavity. DETAILED DESCRIPTION
[0016] In order to explain the technical content, achieved objectives and effects of the present invention in detail, the following is an explanation in conjunction with the implementation modes and the accompanying drawings.
[0017] Please refer to Figure 1 to Figure 2 , 1. A drug eluting balloon, comprising:
[0018] A catheter 1, a balloon 2 is provided at one end of the catheter 1, the balloon 2 includes a first cavity 21 and a second cavity 23, the second cavity 23 is an annular structure surrounding the outside of the first cavity 21, the outer wall of the second cavity 23 is provided with a drug coating 231, the second cavity 23 is communicated with the first cavity 21, there is a gap between the first cavity 21 and the second cavity 23, an inflation port 11 is provided at one end of the catheter 1 away from the balloon 2, when the balloon 2 is in a filled state, the first cavity 21 is away from the blood vessel wall, and the second cavity 23 is in contact with the blood vessel wall;
[0019] The through pipe 3 is fixedly connected to the inside of the catheter 1. The through pipe 3 is coaxial with the catheter 1. The outer wall of the through pipe 3 and the inner wall of the catheter 1 form a cavity 4. The inflation port 11 is connected to the cavity 4. The first cavity 21 is provided with an air inlet 211, which is connected to the cavity 4.
[0020] In the above embodiment, one end of the catheter 1 provided with the balloon 2 is inserted into the diseased part of the patient's blood vessel, and then the inflation port 11 is connected to the pressure pump, and the gas is inflated with the first cavity 21 through the air inlet 211. After the first cavity 21 is filled and expanded, the gas in the first cavity 21 enters the second cavity 23, and the second cavity 23 is filled and expanded, so that the outer wall of the second cavity 23 fits the blood vessel wall, and blood flows through the gap between the first cavity 21 and the second cavity 23. The second cavity 23 can last for a long time in the diseased area, so that the drug coating on its outer wall is in full contact with the diseased part, thereby ensuring the therapeutic effect of the interventional surgery and reducing the recurrence rate of restenosis at the vascular lesion.
[0021] As an optional implementation, the first cavity 21 and the second cavity 23 are connected via a cavity 22 .
[0022] As an optional implementation, there are four cavities 22 .
[0023] In the above embodiment, by providing four cavities 22, not only the blood flow rate can be increased, but also the stability of the filling and expansion of the second cavity 23 and the stability of the adhesion with the blood vessel wall can be maintained.
[0024] As an optional embodiment, a plurality of developing marks 12 are provided at the portion of the catheter 1 located at the balloon 2 , and the plurality of developing marks 12 are located on the outer wall of the catheter 1 .
[0025] In the above embodiment, whether the balloon 2 has reached the lesion portion can be determined by observing the development mark 12 .
[0026] As an optional implementation, the distance between the outer wall of the through tube 3 and the inner wall of the catheter 1 is 5 mm.
[0027] In the above embodiments, the first cavity 21 is expanded and filled to the maximum extent in a short time, so that the drug coating releases the drug to contact the inner wall of the blood vessel as early as possible, thereby improving the speed of treatment.
[0028] The above description is only an embodiment of the present invention, and does not limit the patent scope of the present invention. Any equivalent transformations made using the contents of the specification and drawings of the present invention, or directly or indirectly applied in the relevant technical field, are also included in the patent protection scope of the present invention.
Claims
1. A drug eluting balloon, characterized in that: include: A catheter, wherein a balloon is provided at one end of the catheter, the balloon comprising a first cavity and a second cavity, the second cavity being an annular structure surrounding the outside of the first cavity, the outer wall of the second cavity being provided with a drug coating, the second cavity being communicated with the first cavity, a gap being provided between the first cavity and the second cavity, an inflation port being provided at one end of the catheter away from the balloon, and when the balloon is in a filled state, the first cavity is away from the blood vessel wall, and the second cavity is in contact with the blood vessel wall; A through pipe is fixedly connected to the inside of the catheter, the through pipe is coaxial with the catheter, the outer wall of the through pipe and the inner wall of the catheter form a cavity, the inflation port is connected to the cavity, and an air inlet is provided at the first cavity, which is connected to the cavity.
2. The drug eluting balloon according to claim 1, characterized in that: The first cavity and the second cavity are connected through a cavity.
3. The drug eluting balloon according to claim 1, characterized in that: There are four cavities.
4. The drug eluting balloon according to claim 1, characterized in that: The catheter is provided with a plurality of developing marks at the balloon portion, and the plurality of developing marks are located on the outer wall of the catheter.
5. The drug eluting balloon according to claim 1, characterized in that: The distance between the outer wall of the through tube and the inner wall of the catheter is 5 mm.
